Top

Published in:

01-05-2015 | Original Article

Reversible infantile mitochondrial diseases

Authors: Veronika Boczonadi, Boglarka Bansagi, Rita Horvath

Published in: Journal of Inherited Metabolic Disease | Issue 3/2015

Abstract

Mitochondrial diseases are usually severe and progressive conditions; however, there are rare forms that show remarkable spontaneous recoveries. Two homoplasmic mitochondrial tRNA mutations (m.14674T>C/G in mt-tRNA^Glu) have been reported to cause severe infantile mitochondrial myopathy in the first months of life. If these patients survive the first year of life by extensive life-sustaining measures they usually recover and develop normally. Another mitochondrial disease due to deficiency of the 5-methylaminomethyl-2-thiouridylate methyltransferase (TRMU) causes severe liver failure in infancy, but similar to the reversible mitochondrial myopathy, within the first year of life these infants may also recover completely. Partial recovery has been noted in some other rare forms of mitochondrial disease due to deficiency of mitochondrial tRNA synthetases and mitochondrial tRNA modifying enzymes. Here we summarize the clinical presentation of these unique reversible mitochondrial diseases and discuss potential molecular mechanisms behind the reversibility. Understanding these mechanisms may provide the key to treatments of potential broader relevance in mitochondrial disease, where for the majority of the patients no effective treatment is currently available.

Available only for authorised users

Baruffini E, Dallabona C, Invernizzi F et al (2013) MTO1 mutations are associated with hypertrophic cardiomyopathy and lactic acidosis and cause respiratory chain deficiency in humans and yeast. Hum Mutat 34:1501–1509CrossRefPubMedCentralPubMed

Boczonadi V, Smith PM, Pyle A et al (2013) Altered 2-thiouridylation impairs mitochondrial translation in reversible infantile respiratory chain deficiency. Hum Mol Genet 22:4602–4615CrossRefPubMedCentralPubMed

Chrzanowska-Lightowlers ZM, Horvath R, Lightowlers RN (2010) 175th ENMC International Workshop: mitochondrial protein synthesis in health and disease, 25-27th June 2010, Naarden, The Netherlands. Neuromuscul Disord 21:142–147CrossRefPubMed

DiMauro S, Nicholson JF, Hays AP, Eastwood AB, Koenigsberger R, DeVivo DC (1981) Benign infantile mitochondrial myopathy due to reversible cytochrome c oxidase deficiency. Trans Am Neurol Assoc 106:205–207PubMed

DiMauro S, Nicholson JF, Hays AP, Eastwood AB, Papadimitriou A, Koenigsberger R, DeVivo DC (1983) Benign infantile mitochondrial myopathy due to reversible cytochrome c oxidase deficiency. Ann Neurol 14:226–234CrossRefPubMed

Gaignard P, Gonzales E, Ackermann O et al (2013) Mitochondrial infantile liver disease due to TRMU gene mutations: three New cases. JIMD Rep 11:117–123CrossRefPubMedCentralPubMed

Ghezzi D, Baruffini E, Haack TB et al (2012) Mutations of the mitochondrial-tRNA modifier MTO1 cause hypertrophic cardiomyopathy and lactic acidosis. Am J Hum Genet 90:1079–1087CrossRefPubMedCentralPubMed

Guan MX, Yan Q, Li X et al (2006) Mutation in TRMU related to transfer RNA modification modulates the phenotypic expression of the deafness-associated mitochondrial 12S ribosomal RNA mutations. Am J Hum Genet 79:291–302CrossRefPubMedCentralPubMed

Horvath R, Kemp JP, Tuppen HA et al (2009) Molecular basis of infantile reversible cytochrome c oxidase deficiency myopathy. Brain 132:3165–3174CrossRefPubMedCentralPubMed

Kemp JP, Smith PM, Pyle A et al (2011) Nuclear factors involved in mitochondrial translation cause a subgroup of combined respiratory chain deficiency. Brain 134:183–195CrossRefPubMedCentralPubMed

Lax NZ, Gnanapavan S, Dowson SJ et al (2013) Early-onset cataracts, spastic paraparesis, and ataxia caused by a novel mitochondrial tRNAGlu (MT-TE) gene mutation causing severe complex I deficiency: a clinical, molecular, and neuropathologic study. J Neuropathol Exp Neurol 72:164–175CrossRefPubMed

Levinger L, Mörl M, Florentz C (2004) Mitochondrial tRNA 3′ end metabolism and human disease. Nucleic Acids Res 32:5430–5441CrossRefPubMedCentralPubMed

Levonen AL, Lapatto R, Saksela M, Raivio KO (2000) Human cystathionine gamma-lyase: developmental and in vitro expression of two isoforms. Biochem J 347:291–295CrossRefPubMedCentralPubMed

Macmillan CJ, Shoubridge EA (1996) Mitochondrial DNA depletion: prevalence in a pediatric population referred for neurologic evaluation. Pediatr Neurol 14:203–210CrossRefPubMed

Mancuso M, Orsucci D, Logerfo A et al (2010) Oxidative stress biomarkers in mitochondrial myopathies, basally and after cysteine donor supplementation. J Neurol 257:774–781CrossRefPubMed

Mimaki M, Hatakeyama H, Komaki H et al (2010) Reversible infantile respiratory chain deficiency: a clinical and molecular study. Ann Neurol 68:845–854CrossRefPubMed

Morten KJ, Ashley N, Wijburg F et al (2007) Liver mtDNA content increases during development: a comparison of methods and the importance of age- and tissue-specific controls for the diagnosis of mtDNA depletion. Mitochondrion 7:386–395CrossRefPubMed

Nonaka I, Koga Y, Shikura K et al (1988) Muscle pathology in cytochrome c oxidase deficiency. Acta Neuropathol 77:152–160PubMed

Roodhooft AM, Van Acker KJ, Martin JJ, Ceuterick C, Scholte HR, Luyt-Houwen IE (1986) Benign mitochondrial myopathy with deficiency of NADH-CoQ reductase and cytochrome c oxidase. Neuropediatrics 17:221–226CrossRefPubMed

Rorbach J, Yusoff AA, Tuppen H et al (2008) Overexpression of human mitochondrial valyl tRNA synthetase can partially restore levels of cognate mt-tRNAVal carrying the pathogenic C25U mutation. Nucleic Acids Res 36:3065–3074CrossRefPubMedCentralPubMed

Rötig A (2011) Human diseases with impaired mitochondrial protein synthesis. Biochim Biophys Acta 1807:1198–1205CrossRefPubMed

Russell O, Turnbull D (2014) Mitochondrial DNA disease-molecular insights and potential routes to a cure. Exp Cell Res 325:38–43CrossRefPubMedCentralPubMed

Salmi H, Leonard JV, Rahman S, Lapatto R (2012) Plasma thiol status is altered in children with mitochondrial diseases. Scand J Clin Lab Invest 72:152–157CrossRefPubMed

Salo MK, Rapola J, Somer H, Pihko H, Koivikko M, Tritschler HJ, DiMauro S (1992) Reversible mitochondrial myopathy with cytochrome c oxidase deficiency. Arch Dis Child 67:1033–1035CrossRefPubMedCentralPubMed

Sasarman F, Antonicka H, Horvath R, Shoubridge EA (2011) The 2-thiouridylase function of the human MTU1 (TRMU) enzyme is dispensable for mitochondrial translation. Hum Mol Genet 20:4634–4643CrossRefPubMed

Schara U, von Kleist-Retzow JC, Lainka E et al (2011) Acute liver failure with subsequent cirrhosis as the primary manifestation of TRMU mutations. J Inherit Metab Dis 34:197–201CrossRefPubMed

Smits P, Smeitink J, van den Heuvel L (2010) Mitochondrial translation and beyond: processes implicated in combined oxidative phosphorylation deficiencies. J Biomed Biotechnol 2010:737385CrossRefPubMedCentralPubMed

Steenweg ME, Ghezzi D, Haack T et al (2012) Leukoencephalopathy with thalamus and brainstem involvement and high lactate ‘LTBL’ caused by EARS2 mutations. Brain 135:1387–1394CrossRefPubMed

Sturman JA, Gaull G, Raiha NC (1970) Absence of cystathionase in human fetal liver: is cystine essential? Science 169:74–76CrossRefPubMed

Taanman JW, Hall RE, Tang C, Marusich MF, Kennaway NG, Capaldi RA (1993) Tissue distribution of cytochrome c oxidase isoforms in mammals. Characterization with monoclonal and polyclonal antibodies. Biochim Biophys Acta 1225:95–100CrossRefPubMed

Talim B, Pyle A, Griffin H et al (2013) Multisystem fatal infantile disease caused by a novel homozygous EARS2 mutation. Brain 136:e228CrossRefPubMed

Taylor RW, Pyle A, Griffin H, et al (2014) Whole exome sequencing defines the genetic basis of multiple mitochondrial respiratory chain complex deficiency. JAMA in press June 2014

Tritschler HJ, Bonilla E, Lombes A et al (1991) Differential diagnosis of fatal and benign cytochrome c oxidase-deficient myopathies of infancy: an immunohistochemical approach. Neurology 41:300–305CrossRefPubMed

Tuppen HA, Blakely EL, Turnbull DM, Taylor RW (2010) Mitochondrial DNA mutations and human disease. Biochim Biophys Acta 1797:113–128CrossRefPubMed

Uusimaa J, Jungbluth H, Fratter C et al (2011) Reversible infantile respiratory chain deficiency is a unique, genetically heterogenous mitochondrial disease. J Med Genet 48:660–668CrossRefPubMed

Viscomi C, Burlina AB, Dweikat I et al (2010) Combined treatment with oral metronidazole and N-acetylcysteine is effective in ethylmalonic encephalopathy. Nat Med 16:869–871CrossRefPubMed

Wada H, Woo M, Nishio H et al (1996) Vascular involvement in benign infantile mitochondrial myopathy caused by reversible cytochrome c oxidase deficiency. Brain Dev 18:263–268CrossRefPubMed

Zeharia A, Shaag A, Pappo O et al (2009) Acute infantile liver failure due to mutations in the TRMU gene. Am J Hum Genet 85:401–407CrossRefPubMedCentralPubMed

Zeviani M, Peterson P, Servidei S, Bonilla E, DiMauro S (1987) Benign reversible muscle cytochrome c oxidase deficiency: a second case. Neurology 37:64–67CrossRefPubMed

Title: Reversible infantile mitochondrial diseases
Authors: Veronika Boczonadi
Boglarka Bansagi
Rita Horvath
Publication date: 01-05-2015
Publisher: Springer Netherlands
Published in: Journal of Inherited Metabolic Disease / Issue 3/2015
Print ISSN: 0141-8955
Electronic ISSN: 1573-2665
DOI: https://doi.org/10.1007/s10545-014-9784-6

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2015

Dietary management in glycogen storage disease type III: what is the evidence?

The spectrum of pyruvate oxidation defects in the diagnosis of mitochondrial disorders

Erratum to: TMEM70 deficiency: long-term outcome of 48 patients

Next generation mitochondrial disease: change in diagnostics with eyes on therapy

Skeletal muscle quantitative nuclear magnetic resonance imaging follow-up of adult Pompe patients

Ten years of the international Pompe survey: patient reported outcomes as a reliable tool for studying treated and untreated children and adults with non-classic Pompe disease

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials